SALT LAKE CITY and TORONTO, March 11,
2015 /PRNewswire/ -- EastGate Biotech Corp. (OTCBB:
ETBI), an emerging pharmaceutical company aimed at utilizing drug
delivery innovations in the development of improved novel
formulations and alternative dosage forms of existing biologically
active molecules has received a purchase order from its
newly-engaged Canadian distributor Preferred Nutrition
(www.pno.ca). The company has already received a cash
deposit for this initial order.
The first order by Preferred Nutrition was placed for
E-drops - the Company's natural and herbal alternative that helps
the body to rid of UTI infections painlessly and effectively
without side effects of antibiotics or synthetic drugs.
Preferred Nutrition Inc. is a Canadian premier distribution
company founded in 2002. It primarily distributes to
approximately 1,200 health food stores across Canada. It
represents 5 top product lines for a total of 78 products in the
vitamin and supplement category.
Information on EastGate's natural product line can be found at
www.nano-essentials.com Previously, the company
announced a distributor for its nutraceutical product line
including E-drops in the United
States under its own private label.
"We are pleased to have received this purchase order from
Preferred Nutrition so soon after their engagement," says
Anna Gluskin, EastGate's CEO.
"We look forward to having our products on the shelves of health
food stores across Canada and to
commence our revenue stream which is one of the Key
Performance Indicators for market analysts and investors," states
Ms. Gluskin.
Cautionary statement on forward-looking information
All statements, other than statements of historical fact,
contained or incorporated by reference in this news release
constitute "forward-looking information" or "forward-looking
statements" within the meaning of certain securities laws,
including the provisions for "safe harbour" under the United States
Private Securities Litigation Reform Act of 1995 and are based on
expectations, estimates and projections as of the date of this news
release.
The words "anticipates", "plans", "expects", "indicate",
"intend", "scheduled", "estimates", "forecasts", "focus",
"guidance", "initiative", "model", "methodology", "outlook",
"potential", "projected", "pursue", "strategy", "study", "targets",
or "believes", or variations of or similar such words and phrases
or statements that certain actions, events or results "may",
"could", "would", or "should", "might", or "way forward", "will be
taken", "will occur" or "will be achieved" and similar expressions
identify forward-looking statements. Forward-looking statements are
necessarily based upon a number of estimates and assumptions that
are inherently subject to significant business, economic and
competitive risks, uncertainties and contingencies. The risks,
estimates, models and assumptions contained or incorporated by
reference in this release, include those identified from time to
time in the reports filed by EastGate with the SEC, which should be
considered together with any forward-looking statement.
EastGate undertakes no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACT: Rose Perri
1-647-692-0652
Email: information@eastgatepharmaceuticals.com
Website: www.EastGateBiotech.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/eastgate-biotech-receives-purchase-order-from-its-canadian-distributor-for-nutraceutical-products-300048728.html
SOURCE EastGate Biotech Corp.